Inventiva Sa - Adr (IVA)

$1.89

+0.17

(+9.88%)▲

Market is closed - opens 7 PM, 14 Oct 2024

Performance

  • $1.72
    $1.89
    $1.89
    downward going graph

    8.99%

    Downside

    Day's Volatility :8.99%

    Upside

    0.0%

    downward going graph
  • $1.53
    $4.75
    $1.89
    downward going graph

    19.05%

    Downside

    52 Weeks Volatility :67.79%

    Upside

    60.21%

    downward going graph

Returns

PeriodInventiva Sa - AdrSector (Health Care)Index (Russel 2000)
3 Months
-29.16%
3.8%
0.0%
6 Months
-42.38%
10.8%
0.0%
1 Year
-51.66%
18.2%
0.0%
3 Years
-86.16%
20.8%
-22.2%

Highlights

Market Capitalization
99.0M
Book Value
- $0.62
Earnings Per Share (EPS)
-2.25
Profit Margin
0.0%
Operating Margin TTM
-1911.08%
Return On Assets TTM
-69.19%
Return On Equity TTM
-1642.76%
Revenue TTM
19.3M
Revenue Per Share TTM
0.38
Quarterly Revenue Growth YOY
-58.699999999999996%
Gross Profit TTM
18.8M
EBITDA
-99.8M
Diluted Eps TTM
-2.25
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Inventiva Sa - Adr(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
11
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1610.76%

Current $1.89
Target $32.33

Company Financials

FY18Y/Y Change
Revenue
3.6M
↓ 50.97%
Net Income
-38.2M
↑ 95.12%
Net Profit Margin
-1.1K%
↓ 787.3%
FY19Y/Y Change
Revenue
7.8M
↑ 118.89%
Net Income
-33.6M
↓ 10.1%
Net Profit Margin
-431.85%
↑ 619.67%
FY20Y/Y Change
Revenue
452.5K
↓ 94.68%
Net Income
-38.5M
↑ 4.64%
Net Profit Margin
-8.5K%
↓ 8068.96%
FY21Y/Y Change
Revenue
4.7M
↑ 1027.42%
Net Income
-56.1M
↑ 56.96%
Net Profit Margin
-1.2K%
↑ 7317.31%
FY22Y/Y Change
Revenue
12.9M
↑ 190.39%
Net Income
-57.4M
↑ 9.34%
Net Profit Margin
-445.64%
↑ 737.86%
FY23Y/Y Change
Revenue
19.1M
↑ 43.5%
Net Income
-120.5M
↑ 103.46%
Net Profit Margin
-631.84%
↓ 186.2%
Q4 FY22Q/Q Change
Revenue
16.3M
-
Net Income
-26.3M
-
Net Profit Margin
-160.86%
-
Q2 FY23Q/Q Change
Revenue
6.6M
-
Net Income
-55.3M
-
Net Profit Margin
-834.63%
-
Q4 FY23Q/Q Change
Revenue
15.6M
↑ 135.22%
Net Income
-55.2M
↓ 0.2%
Net Profit Margin
-354.12%
↑ 480.51%
Q1 FY24Q/Q Change
Revenue
16.5M
↑ 6.2%
Net Income
-55.2M
↑ 0.0%
Net Profit Margin
-333.46%
↑ 20.66%
FY18Y/Y Change
Total Assets
90.8M
↑ 7.32%
Total Liabilities
20.7M
↑ 75.86%
FY19Y/Y Change
Total Assets
63.3M
↓ 28.63%
Total Liabilities
17.3M
↓ 14.54%
FY20Y/Y Change
Total Assets
169.0M
↑ 143.89%
Total Liabilities
33.7M
↑ 77.98%
FY21Y/Y Change
Total Assets
137.9M
↓ 12.19%
Total Liabilities
37.4M
↑ 19.53%
FY22Y/Y Change
Total Assets
122.8M
↓ 4.9%
Total Liabilities
74.6M
↑ 112.96%
FY23Y/Y Change
Total Assets
69.1M
↓ 40.4%
Total Liabilities
101.6M
↑ 44.05%
Q2 FY22Q/Q Change
Total Assets
114.7M
↓ 10.58%
Total Liabilities
40.9M
-
Q4 FY22Q/Q Change
Total Assets
122.8M
↑ 7.02%
Total Liabilities
74.6M
↑ 82.4%
Q2 FY23Q/Q Change
Total Assets
76.8M
↓ 38.95%
Total Liabilities
85.1M
-
Q4 FY23Q/Q Change
Total Assets
77.3M
↑ 0.0%
Total Liabilities
110.8M
↑ 29.44%
Q1 FY24Q/Q Change
Total Assets
69.1M
↓ 2.37%
Total Liabilities
101.6M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
-38.9M
↑ 101.19%
Investing Cash Flow
-477.8K
↓ 106.81%
Financing Cash Flow
36.7M
↓ 28.32%
FY19Y/Y Change
Operating Cash Flow
-31.6M
↓ 16.96%
Investing Cash Flow
-917.9K
↑ 96.67%
Financing Cash Flow
9.3M
↓ 74.04%
FY20Y/Y Change
Operating Cash Flow
-37.2M
↑ 7.7%
Investing Cash Flow
-10.4M
↑ 935.96%
Financing Cash Flow
135.8M
↑ 1232.94%
FY21Y/Y Change
Operating Cash Flow
-53.8M
↑ 55.7%
Investing Cash Flow
-2.0M
↓ 79.05%
Financing Cash Flow
28.8M
↓ 77.21%
Q2 FY22Q/Q Change
Operating Cash Flow
-27.7M
↑ 100.0%
Investing Cash Flow
-141.7K
↑ 0.0%
Financing Cash Flow
14.8M
↑ 100.0%
Q3 FY22Q/Q Change
Operating Cash Flow
-22.6M
↓ 13.75%
Investing Cash Flow
-3.9M
↑ 2773.88%
Financing Cash Flow
-1.1M
↓ 107.72%
Q4 FY22Q/Q Change
Operating Cash Flow
-19.8M
↓ 17.29%
Investing Cash Flow
-4.1M
↑ 0.0%
Financing Cash Flow
24.7M
↓ 2265.91%
Q1 FY23Q/Q Change
Operating Cash Flow
-22.6M
↑ 20.9%
Investing Cash Flow
-3.9M
↑ 0.0%
Financing Cash Flow
-1.1M
↓ 104.62%
Q2 FY23Q/Q Change
Operating Cash Flow
-45.2M
↑ 100.0%
Investing Cash Flow
-3.9M
↑ 0.0%
Financing Cash Flow
-2.2M
↑ 100.0%

Technicals Summary

Sell

Neutral

Buy

Inventiva Sa - Adr is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inventiva Sa - Adr
Inventiva Sa - Adr
-14.48%
-42.38%
-51.66%
-86.16%
-86.5%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-11.92%
13.03%
20.39%
82.8%
232.53%
Novo Nordisk A/s
Novo Nordisk A/s
-12.32%
-3.12%
18.68%
139.03%
361.43%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
5.16%
92.5%
70.0%
35.85%
259.26%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.58%
21.23%
28.8%
164.82%
177.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inventiva Sa - Adr
Inventiva Sa - Adr
NA
NA
NA
0.0
-16.43
-0.69
NA
-0.62
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.88
26.88
1.38
45.01
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.83
40.83
1.8
3.37
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.38
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.58
0.33
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inventiva Sa - Adr
Inventiva Sa - Adr
Buy
$99.0M
-86.5%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.1B
232.53%
26.88
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$523.9B
361.43%
40.83
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
259.26%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$124.3B
177.5%
32.84
-4.74%

Insights on Inventiva Sa - Adr

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.1% return, outperforming this stock by 121.9%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 35.8% return, outperforming this stock by 122.0%

Institutional Holdings

  • Yiheng Capital LLC

    5.05%

  • NEA Management Company, LLC

    2.79%

  • Bvf Inc

    1.31%

  • Commonwealth Equity Services Inc

    0.08%

  • UBS Group AG

    0.02%

Company Information

Organization
Inventiva Sa - Adr
Employees
120
CEO
Mr. Frederic Cren
Industry
Health Technology

Discover More

FAQs